ExCellThera is at the forefront of cell expansion and rejuvenation technologies, particularly focusing on hematopoietic stem cells (HSCs). Their proprietary Enhance™ Platform is designed to significantly improve the expansion of primitive HSCs from various sources, enabling the delivery of higher doses of functional cells for cell and gene therapies. This platform not only enhances the quantity of stem cells but also counteracts the aging effects often seen in older or manipulated cells, thereby preserving their "stemness" and quiescence. The company has successfully treated over 100 patients with UM171-expanded cells, demonstrating the clinical efficacy of their approach, which has been validated through multiple scientific publications.

In addition to the Enhance™ Platform, ExCellThera is advancing its UM171 cell therapy, which is recognized as a standard for ex vivo HSC expansion in the field of cell and gene therapy. The UM171 molecule has been shown to maintain superior stemness characteristics in cultured stem cells and is supported by a Drug Master File (DMF), ensuring its compliance with Good Manufacturing Practices (GMP). ExCellThera is also developing a pre-clinical pipeline of proprietary HSC-based cell and gene therapies targeting various diseases, including blood cancers, thereby positioning itself as a leader in innovative therapeutic solutions for hematological malignancies and beyond.

Canada

ExCellThera is an advanced clinical-stage company specializing in cell expansion and engineering, providing molecules and bioengineering solutions to expand stem cells.

ExCellThera

Company Details